Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9207951 | 0.80 | POLB (0.49) | POLBGAAMAPTENPP2 | |
| SCHEMBL13449908 | 0.78 | POLB (0.47) | POLBGAAMAPTENPP2 | |
| SCHEMBL5634677 | 0.75 | POLB (0.45) | POLBGAAMAPTENPP2 | |
| SCHEMBL14546802 | 0.75 | GAA (0.45) | POLBGAAMAPTENPP2 | |
| SCHEMBL7598100 | 0.75 | GAA (0.49) | POLBGAAMAPTENPP2 | |
| SCHEMBL23919414 | 0.74 | POLB (0.47) | POLBGAAMAPT | |
| SCHEMBL8592976 | 0.72 | MAPT (0.43) | POLBGAAMAPTENPP2 | |
| SCHEMBL22895170 | 0.72 | GAA (0.46) | POLBGAAMAPTENPP2 | |
| SCHEMBL14938566 | 0.72 | GAA (0.43) | POLBGAAMAPTENPP2 | |
| SCHEMBL3717367 | 0.72 | POLB (0.50) | POLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-09-05 | — | — | US | disclosed |
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-09-05 | — | — | US | disclosed |
| WO-2012001076-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | AQP3, SUCNR1, AQP1 | POLB 2380/4885GAA 1686/4885MAPT 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.